MELBOURNE, Australia--(BUSINESS WIRE)--Cogstate Ltd (ASX:CGS), a cognitive science and medical technology company, today announced the latest version of its remote cognitive assessment solution for pre-screening participants in clinical trials, Precision Recruitment™ 2.1.
Precision Recruitment™ supports clinical trials in more effectively recruiting participants with specific levels of cognitive impairment using remote cognitive assessment technology. Designed to be flexibly integrated into existing recruitment workflows, Precision Recruitment™ is rapidly deployed to identify the right patients, accelerate the recruitment process and reduce costly on-site screen failures.
This new version release further optimizes patient recruitment with study-specific prescreening workflows and a delivery platform that allows for self-administered cognitive assessments on any modality including tablet-based assessments. Other important new features include:
These capabilities incorporate extensive usability testing in healthy elderly populations, ensuring high completion rates by this target population.
Of the company’s recent product release, Cogstate CEO, Brad O’Connor said, “Growing understanding of Alzheimer’s disease pathology has increased the emphasis on clinical trials toward earlier intervention in the disease, presenting significant enrollment challenges as recruitment efforts must now focus outreach strategies toward populations who are at risk for early AD. The use of remote cognitive assessment technologies to pre-screen participants is a critical element in driving efficiencies in this new paradigm of recruitment.”
"We’ve developed a technology platform that allows us to deliver our scientifically validated cognitive assessments in new settings and modalities," said Craig Gravina, Cogstate CTO. "From computer-based assessments in the clinic to self-guided at-home assessments via PC or tablet, we’ve demonstrated equivalence and are leveraging these proven cognitive measures in new ways to help solve some of the critical challenges facing clinical research."
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.